| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Fu,Hui-Dong | Chairman | 0.00% | |
| Zhang,Ming-Zheng | Director | 0.00% | |
| Wu,Guo-Long | Director | 33.96% | EXCELSIOR MEDICAL CO., LTD. |
| Zhou,Chen-Xiao | Director | 33.96% | EXCELSIOR MEDICAL CO., LTD. |
| Xue,Fu-Quan | Director | 33.96% | EXCELSIOR MEDICAL CO., LTD. |
| Fu,Ruo-Xuan | Director | 0.00% | |
| Liao,Yi-Xing | Independent Director | 0.00% | |
| Ceng,Cui-Zhen | Independent Director | 0.00% | |
| Lin,Feng-Zhi | Independent Director | 0.00% |
下載完整報告查看完整數據
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 351,235 | 1,572,704 | 1,593,502 |
| Operating cost | 207,955 | 943,483 | 990,448 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 143,280 | 629,221 | 603,054 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 143,280 | 629,221 | 603,054 |
| Operating expenses | 101,651 | 384,133 | 334,495 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | 41,629 | 245,088 | 268,559 |
| Non-operating income and expenses | 16,744 | 44,579 | 28,746 |
| Net profit (loss) before tax | 58,373 | 289,667 | 297,305 |
| Income tax expense (benefits) | 11,475 | 51,610 | 59,543 |
| Net profit (loss) of ongoing business for the current period | 46,898 | 238,057 | 237,762 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | 46,898 | 238,057 | 237,762 |
| Other comprehensive profit (loss), net | -10,162 | 16,328 | 34,075 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | 36,736 | 254,385 | 271,837 |
| Net profit (loss) attributable to owners of parent company | 41,537 | 205,393 | 210,319 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | 5,361 | 32,664 | 27,443 |
| Comprehensive profit (loss) attributable to owners of parent company | 31,156 | 222,026 | 244,150 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | 5,580 | 32,359 | 27,687 |
| Basic earnings per share (yuan) | 1 | 5 | 6 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | -47,574 | 224,113 | 360,946 |
| Net cash inflows (outflows) from investing activities | 136,001 | -61,593 | -28,690 |
| Net cash inflow (outflow) from financing activities | -21,987 | -379,008 | -85,398 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | -890 | 17,829 | -1,046 |
| Increase (decrease) in cash and cash equivalents in the current period | 65,550 | -198,659 | 245,812 |
| Beginning balance of cash and cash equivalents | 726,279 | 924,938 | 679,126 |
| Ending balance of cash and cash equivalents | 791,829 | 726,279 | 924,938 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 1,909,710 | 1,906,632 | 2,092,959 |
| Non-current asset | 1,053,783 | 1,097,709 | 984,062 |
| Total asset | 2,963,493 | 3,004,341 | 3,077,021 |
| Current liability | 959,567 | 869,163 | 1,079,530 |
| Non-current liability | 358,306 | 375,649 | 293,560 |
| Total liability | 1,317,873 | 1,244,812 | 1,373,090 |
| share capital | 363,000 | 363,000 | 330,000 |
| Equity - secruity token | - | - | - |
| capital reserve | 627,357 | 627,357 | 626,361 |
| retained earning | 364,215 | 473,323 | 523,272 |
| Other equity | 62,222 | 72,603 | 56,378 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 1,416,794 | 1,536,283 | 1,536,011 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | 228,826 | 223,246 | 167,920 |
| Total Equity | 1,645,620 | 1,759,529 | 1,703,931 |
| Share capital awaiting retirement (unit: share) | 0 | - | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 39 | 42 | 46 |
Others
2018
Return rent
2014
Stop execution
2019
Provisional injunction
2012
Time-limited prosecution
2012
Third party objection suit, etc.
2019
Confirmation of the existence of employment relationship, etc
2023
Infringement of trademark rights related to property rights disputes
2024
Others
2019
Pay price
2012, 2019
Payment order
2013, 2014, 2024
Return property
2020
Pay for the goods
2013
Motion of objection
2021, 2022
Invalidating Judgment
2009
Promissory note ruling
2013
Determine legal expenses
2020
Pharmaceutical Affairs Law
2009
Invalidating Judgment (Note)
2013, 2014
Return rental property, etc.
2009
Petition filed for public summons
2008, 2013, 2014
Motion of objection (return of deposit)
2023
